Drug Approval | December 27, 2023
Eugia Pharma Specialities receives USFDA final approval for Posaconazole Injection
The product is expected to be launched in December 2023
The product is expected to be launched in December 2023
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
The product will be manufactured at Lupin's Pithampur facility in India
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
Subscribe To Our Newsletter & Stay Updated
